Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
12 April 2021 - 10:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2021
Commission File Number 001-37381
MEDIGUS LTD.
(Translation of registrant’s name into English)
Omer
Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel
(Address of principal
executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
EXPLANATORY NOTE
On
April 12, 2021, Medigus Ltd. issued a press release titled: “Polyrizon Commenced a Pre-Clinical Study Testing Several Formulations
of its Bio-Gel for Protection against Coronavirus.” A copy of this press release is furnished herewith as exhibit 99.1.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
MEDIGUS LTD.
|
|
|
|
Date: April 12, 2021
|
By:
|
/s/ Oz Adler
|
|
|
Oz Adler
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
3
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2024 to May 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From May 2023 to May 2024